1. Home
  2. FINW vs LCTX Comparison

FINW vs LCTX Comparison

Compare FINW & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FINW
  • LCTX
  • Stock Information
  • Founded
  • FINW 1999
  • LCTX 1990
  • Country
  • FINW United States
  • LCTX United States
  • Employees
  • FINW N/A
  • LCTX N/A
  • Industry
  • FINW Commercial Banks
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FINW Finance
  • LCTX Health Care
  • Exchange
  • FINW Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • FINW 261.6M
  • LCTX 274.0M
  • IPO Year
  • FINW 2021
  • LCTX N/A
  • Fundamental
  • Price
  • FINW $17.80
  • LCTX $1.65
  • Analyst Decision
  • FINW Buy
  • LCTX Strong Buy
  • Analyst Count
  • FINW 4
  • LCTX 4
  • Target Price
  • FINW $20.75
  • LCTX $4.25
  • AVG Volume (30 Days)
  • FINW 15.1K
  • LCTX 1.8M
  • Earning Date
  • FINW 10-29-2025
  • LCTX 11-13-2025
  • Dividend Yield
  • FINW N/A
  • LCTX N/A
  • EPS Growth
  • FINW N/A
  • LCTX N/A
  • EPS
  • FINW 0.96
  • LCTX N/A
  • Revenue
  • FINW $74,999,000.00
  • LCTX $10,914,000.00
  • Revenue This Year
  • FINW $52.89
  • LCTX N/A
  • Revenue Next Year
  • FINW $20.66
  • LCTX $176.00
  • P/E Ratio
  • FINW $18.22
  • LCTX N/A
  • Revenue Growth
  • FINW 10.21
  • LCTX 76.43
  • 52 Week Low
  • FINW $13.49
  • LCTX $0.37
  • 52 Week High
  • FINW $22.49
  • LCTX $1.85
  • Technical
  • Relative Strength Index (RSI)
  • FINW 39.25
  • LCTX 52.28
  • Support Level
  • FINW $17.49
  • LCTX $1.63
  • Resistance Level
  • FINW $18.85
  • LCTX $1.83
  • Average True Range (ATR)
  • FINW 0.90
  • LCTX 0.11
  • MACD
  • FINW -0.21
  • LCTX -0.03
  • Stochastic Oscillator
  • FINW 10.55
  • LCTX 12.00

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: